SCHEMBL3401206

SCHEMBL3401206

Cc1cccc(-c2nc3cc(C)ccc3o2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.79
KDM4E B2RXH2 11/20 0.79
SMN1; SMN2 Q16637 11/20 0.79
NPC1 O15118 10/20 0.79
HPGD P15428 10/20 0.79
CASP3 P42574 3/20 0.79
SENP7 Q9BQF6 3/20 0.79
SENP6 Q9GZR1 3/20 0.79
SENP8 Q96LD8 2/20 0.79
POLB P06746 1/20 0.79
ALDH1A1 P00352 11/20 0.78
MAPT P10636 8/20 0.78
NFKB1 P19838 5/20 0.78
NFKB2 Q00653 5/20 0.78
RELA Q04206 5/20 0.78
TP53 P04637 7/20 0.74
HSD17B10 Q99714 7/20 0.74
L3MBTL1 Q9Y468 3/20 0.74
GLA P06280 1/20 0.74
TDP1 Q9NUW8 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29858577 1.00 RAB9A (0.79) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL152658 0.88 SMN1; SMN2 (1.00) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL29362501 0.88 SMN1; SMN2 (1.00) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL30153418 0.88 RAB9A (1.00) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL3137765 0.88 RAB9A (0.70) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL27652504 0.88 KDM4E (0.70) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL2245287 0.88 RAB9A (0.79) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL26218678 0.88 SMN1; SMN2 (0.66) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL27672723 0.88 RAB9A (0.70) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL2492958 0.88 RAB9A (1.00) RAB9AKDM4ESMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators NIH-DEITR 2017-07-06 US claimed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US claimed
US-9433610-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2016-09-06 US claimed
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-04 US claimed
US-20150157607-A1 Compounds that Enhance Atoh1 Expression MASSACHUSETTS EYE & EAR INFIRMARY 2015-06-11 US claimed
WO-2014145205-A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-09-18 WO claimed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 EP claimed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US claimed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO claimed
US-12239651-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2025-03-04 US disclosed
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-12-03 US disclosed
US-20240299432-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2024-09-12 US disclosed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 US disclosed
US-12018128-B2 Particle-dispersed polyimide precursor solution, method for producing porous polyimide film, and porous polyimide film FUJIFILM BUSINESS INNOVATION CORP. (JP) 2024-06-25 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299432-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 RAB9A 1434/4885KDM4E 673/4885SMN1; SMN2 3919/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 RAB9A 2455/4885KDM4E 3219/4885SMN1; SMN2 4645/4885
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators WNT1, CTNNB1, CTNNBL1 RAB9A 4314/4885KDM4E 2917/4885SMN1; SMN2 4085/4885
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells HES1, NOTCH1, NOTCH4 RAB9A 3020/4885KDM4E 3697/4885SMN1; SMN2 4643/4885
US-20150157607-A1 Compounds that Enhance Atoh1 Expression DACH1, EZH1, CREBBP RAB9A 3293/4885KDM4E 1336/4885SMN1; SMN2 2179/4885
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS WNT1, CTNNB1, CTNNBL1 RAB9A 4168/4885KDM4E 2958/4885SMN1; SMN2 4190/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP RAB9A 3293/4885KDM4E 1336/4885SMN1; SMN2 2179/4885
US-12239651-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 RAB9A 1434/4885KDM4E 673/4885SMN1; SMN2 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.